May 9, 2022
Mental Health
  • The Department of Justice (DOJ) launched an investigation into mental health startup Cerebral, citing “possible violations” of the Controlled Substances Act. The subpoena demands the company turns over a slew of documents related to its prescribing of controlled substances, like Adderall or Xanax. Cerebral is among a handful of virtual care startups that prescribe controlled substances without patients seeing a doctor in-person. The company said it intends to fully cooperate with the investigation. (Article here)